Welcome to LookChem.com Sign In|Join Free
  • or
1-Piperidinecarboxylic acid, 4-[(4-aminophenyl)sulfonyl]-, 1,1-dimethylethyl ester is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

676527-52-9

Post Buying Request

676527-52-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

676527-52-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 676527-52-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,7,6,5,2 and 7 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 676527-52:
(8*6)+(7*7)+(6*6)+(5*5)+(4*2)+(3*7)+(2*5)+(1*2)=199
199 % 10 = 9
So 676527-52-9 is a valid CAS Registry Number.

676527-52-9Relevant academic research and scientific papers

SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF

-

, (2018/08/03)

Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.

TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

-

Page/Page column 137-138, (2011/06/16)

Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.

BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES

-

Page/Page column 198, (2008/06/13)

The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non receptor kinases.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 676527-52-9